|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
Prospective randomized trial to assess the antiviral efficacy of Pegylated Interferon Lambda (180 mcg SC injection) vs.placebo in up to 20 inpatient subjects with COVID-19 infection.
Description: Negative COVID PCR testing 7 days after first lambda doseMeasure: Undetectable COVID PCR at day 7 Time: 1 week
Description: Negative COVID PCR testing 3, 5, 7 and 14 days after first lambda doseMeasure: Undetectable COVID PCR at day 3, 10 and 14 Time: 2 weeks
Description: Daily symptom score improvement during treatment periodMeasure: Percentage of subjects on Lambda vs placebo with symptomatic improvement Time: 2 weeks
Description: Time to event for death, intubation, hospital dischargeMeasure: Percentage of subjects on Lambda vs placebo with improved clinical outcomes Time: 2 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports